With our partner Salesforce, unify sales, marketing and customer service. Accelerate your growth!
DEEPLIFE, a Parisian startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, is revolutionizing pharmaceutical research thanks to its SaaS platform combining generative artificial intelligence and multi-omics data. This technology makes it possible to create digital twins of cells, opening new perspectives for accelerating drug discovery.
The DEEPLIFE platform relies on deep learning algorithms and cellular atlases to carry out in silico simulations. These models identify molecular triggers and enable cellular behavior to be engineered, reducing the time needed to develop new molecules from years to months. A recent partnership with INSERM demonstrated DeepLife’s capacity to produce unprecedented results, particularly for diseases previously considered incurable.
DEEPLIFE primarily targets autoimmune and neurodegenerative diseases, but the platform also aims to explore new applications for more than 8,000 existing drugs. This approach aims to maximize the use of therapeutic resources and meet the needs of patients facing complex pathologies. Early commercial successes include a two-year licensing agreement with a molecule manufacturer, confirming the solution’s relevance to the pharmaceutical industry.
The raising of 10 million euros in Series A, led by Turenne Groupe and YZR Capital, with the participation of Beiersdorf, Groupe Prunay, and historical investors, marks a strategic step for DEEPLIFE. This funding will strengthen the platform’s capabilities, particularly in the areas of autoimmune and neurodegenerative diseases, and support its expansion in the United States.
